表紙：網膜疾患治療薬の市場規模、シェア、成長分析、疾患別、疾患タイプ別、治療技術別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1780199

網膜疾患治療薬の市場規模、シェア、成長分析、疾患別、疾患タイプ別、治療技術別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

Retinal Disease Therapeutics Market Size, Share, and Growth Analysis, By Disorder (Macular Degeneration, Diabetic Eye Disease), By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Region - Industry Forecast 2025-2032

出版日: 2025年07月26日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 804,487円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 941,098円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,077,709円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=151.79円

全表示
概要
目次

概要

サンプル依頼リストに入れる

網膜疾患治療薬の世界市場規模は、2022年に118億米ドルと評価され、2023年の128億6,000万米ドルから2031年には256億3,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは9.0％で成長する見通しです。

世界の網膜疾患治療薬市場は、現在世界で2億5,300万人以上が罹患している網膜障害の有病率の上昇に牽引され、大きな成長を遂げています。この急増する問題は、特に高齢化社会が拡大し続け、50歳以上の視力障害が顕著に集中する中で、ヘルスケアシステムにますます大きな圧力をかけています。特に新興市場における糖尿病罹患率の上昇に伴う網膜疾患の罹患率の上昇が、この課題をさらに悪化させています。しかし、網膜疾患治療に特化した専門医療従事者の流入や、各国における償還制度の強化により、網膜治療における先進治療や革新的ソリューションへのアクセス拡大に向けた道が開かれ、市場は恩恵を受けると予測されます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2021-2023年）

主要企業プロファイル

Regeneron Pharmaceuticals, Inc.（USA）
Roche Holding AG（Switzerland）
Novartis AG（Switzerland）
Allergan（part of AbbVie）（USA）
Bayer AG（Germany）
Oculis（Switzerland）
REGENXBIO Inc.（USA）
Adverum Biotechnologies, Inc.（USA）
Kodiak Sciences Inc.（USA）
EyePoint Pharmaceuticals, Inc.（USA）
Apellis Pharmaceuticals, Inc.（USA）
Iveric Bio, Inc.（USA）（Acquired by Astellas）
Annexon Biosciences（USA）
Hemera Biosciences（USA）（Acquired by Roche）
Gyroscope Therapeutics（UK）（Acquired by Novartis）
Graybug Vision, Inc.（USA）
Clearside Biomedical, Inc.（USA）
Ocuphire Pharma, Inc.（USA）
Lineage Cell Therapeutics, Inc.（USA）
Ocugen, Inc.（USA）

結論と提言

Product Code: SQMIG35H2062

Global Retinal Disease Therapeutics Market size was valued at USD 11.8 billion in 2022 and is poised to grow from USD 12.86 billion in 2023 to USD 25.63 billion by 2031, growing at a CAGR of 9.0% during the forecast period (2024-2031).

The global retinal disease therapeutics market is experiencing significant growth, driven by the rising prevalence of retinal disorders, which currently affect over 253 million individuals worldwide. This burgeoning issue is putting increasing pressure on healthcare systems, particularly as the aging population continues to expand, with a notable concentration of vision impairment among those over 50 years old. The escalating incidence of retinal diseases, especially in the context of rising diabetes rates in emerging markets, is further compounding the challenge. However, the market is projected to benefit from an influx of specialized healthcare professionals dedicated to retinal disease treatment and enhanced reimbursement frameworks in multiple countries, paving the way for expanding access to advanced therapies and innovative solutions in retinal care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related disorders, particularly in more developed nations, is a significant factor propelling the global market for retinal disease therapeutics. A substantial number of individuals worldwide experience conditions such as diabetic retinopathy and age-related macular degeneration (AMD), underscoring the urgent need for effective treatments. As more individuals become aware of these conditions through enhanced health education initiatives, particularly in developing areas, there is a greater emphasis on seeking early intervention to avoid vision loss. This growing awareness and demand for innovative therapeutic solutions are anticipated to further stimulate advancements and expansion within the retinal therapeutics market.

Restraints in the Global Retinal Disease Therapeutics Market

The global retinal disease therapeutics market faces several challenges that may hinder its growth. High expenses associated with retinal treatment therapies can limit patient accessibility and adoption. Moreover, patients often report experiencing short-term side effects, along with potential long-term complications like infections and inflammation following procedures such as laser eye surgery. The risk of unintentional scleral perforation during specific surgical techniques, such as pneumatic retinopexy, may further deter patient willingness to undergo treatment. Additionally, inadequate healthcare infrastructure in developing regions poses a significant obstacle to the advancement of the retinal disease therapeutics market.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is poised for significant growth, driven by the emergence of advanced technologies, particularly in retinal gene therapy. Innovations such as Luxturna, which targets the RPE65 gene mutation to treat inherited conditions like Leber's congenital amaurosis, underline a transformative shift in therapeutic approaches. As several promising retinal gene therapies are currently undergoing clinical trials using recombinant viruses, their anticipated approval and market entry are set to further enhance treatment options. Between 2022 and 2028, this advancement in gene therapy is projected to significantly expand the market, catering to the increasing demand for effective solutions for retinal disorders.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2024-2031)

Market Overview
Macular Degeneration
Diabetic Eye Disease
Retinal Detachment
Retinoblastoma
Macular Pucker
Macular Hole
Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2024-2031)

Market Overview
Genetic
Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2024-2031)

Market Overview
Laser
Freezing
Implanting
Indenting
Pneumatic Retinopexy
Scleral Buckling
Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2024-2031)

Market Overview
Oral
Topical
Intravitreal
Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2024-2031)

Market Overview
Hospitals
Ambulatory Surgical Centers
Home Healthcare
Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2024-2031)

Market Overview
Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Retinal Disease Therapeutics Market Size & CAGR (2024-2031)

North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- US
- Canada
Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (part of AbbVie) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oculis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
REGENXBIO Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EyePoint Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apellis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iveric Bio, Inc. (USA) (Acquired by Astellas)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Annexon Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemera Biosciences (USA) (Acquired by Roche)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gyroscope Therapeutics (UK) (Acquired by Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocuphire Pharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lineage Cell Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocugen, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

網膜疾患治療薬の市場規模、シェア、成長分析、疾患別、疾患タイプ別、治療技術別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

Retinal Disease Therapeutics Market Size, Share, and Growth Analysis, By Disorder (Macular Degeneration, Diabetic Eye Disease), By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

網膜疾患治療薬市場規模：疾患別& CAGR（2024-2031）

網膜疾患治療薬市場規模：疾患タイプ別& CAGR（2024-2031）

網膜疾患治療薬市場規模：治療技術別& CAGR（2024-2031）

網膜疾患治療薬市場規模：投与経路別& CAGR（2024-2031）

網膜疾患治療薬市場規模：エンドユーザー別& CAGR（2024-2031）

網膜疾患治療薬市場規模：流通チャネル別& CAGR（2024-2031）

網膜疾患治療薬市場規模：地域別& CAGR（2024-2031）